Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population

George N. Ioannou, Olivia B. Morrow, Marah L. Connole, Sum P. Lee – 23 June 2009 – Little is known about the impact of dietary factors on the progression of liver disease. Our aim was to determine whether dietary intake was associated with the risk of cirrhosis‐related or liver cancer–related death or hospitalization in the U.S. population.

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

Alexis St. George, Adrian Bauman, Amanda Johnston, Geoffrey Farrell, Tien Chey, Jacob George – 23 June 2009 – Nonalcoholic fatty liver disease, characterized by elevated liver enzymes, central obesity, and insulin resistance, is becoming increasingly prevalent. The effects of changes in physical activity on the metabolic profile of this group have not been reported. We assessed at 3 months the impact of a behavior change‐based lifestyle intervention on physical activity and the effects of this change on the metabolic profile of people with fatty liver disease.

Diferentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation

Mario Strazzabosco, Romina Fiorotto, Saida Melero, Shannon Glaser, Heather Francis, Carlo Spirli, Gianfranco Alpini – 23 June 2009 – Cyclic adenosine monophosphate (cAMP) is generated by adenylyl cyclases (ACs), a group of enzymes with different tissue specificity and regulation. We hypothesized that AC isoforms are heterogeneously expressed along the biliary tree, are associated with specific secretory stimuli, and are differentially modulated in cholestasis.

L‐ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats

Nathan A. Davies, Gavin Wright, Lars M. Ytrebø, Vanessa Stadlbauer, Ole‐Martin Fuskevåg, Claudia Zwingmann, D. Ceri Davies, Abeba Habtesion, Stephen J. Hodges, Rajiv Jalan – 23 June 2009 – Treatment of hyperammonemia and hepatic encephalopathy in cirrhosis is an unmet clinical need.

Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis

Karlin Raja Karlmark, Ralf Weiskirchen, Henning W. Zimmermann, Nikolaus Gassler, Florent Ginhoux, Christian Weber, Miriam Merad, Tom Luedde, Christian Trautwein, Frank Tacke – 23 June 2009 – In addition to liver‐resident Kupffer cells, infiltrating immune cells have recently been linked to the development of liver fibrosis. Blood monocytes are circulating precursors of tissue macrophages and can be divided into two functionally distinct subpopulations in mice: Gr1hi (Ly6Chi) and Gr1lo (Ly6Clo) monocytes.

Hypoxia‐inducible factor 1α is up‐regulated by oncostatin M and participates in oncostatin M signaling

Stefan Vollmer, Valérie Kappler, Jakub Kaczor, Daniela Flügel, Catherine Rolvering, Nobuyuki Kato, Thomas Kietzmann, Iris Behrmann, Claude Haan – 23 June 2009 – The interleukin‐6–type cytokine oncostatin M (OSM) acts via the Janus kinase/signal transducer and activator of transcription pathway as well as via activation of mitogen‐activated protein kinases and is known to critically regulate processes such as liver development and regeneration, hematopoiesis, and angiogenesis, which are also determined by hypoxia with the hypoxia‐inducible factor 1α (HIF1α) as a key component.

Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells

Shyam Kottilil, Michael Y. Yan, Kristin N. Reitano, Xiaozhen Zhang, Richard Lempicki, Gregg Roby, Marybeth Daucher, Jun Yang, Karoll J. Cortez, Marc Ghany, Michael A. Polis, Anthony S. Fauci – 23 June 2009 – Coinfection with hepatitis C virus (HCV) is present in one‐third of all human immunodeficiency virus (HIV)‐infected individuals in the United States and is associated with rapid progression of liver fibrosis and poor response to pegylated interferon (IFN) and ribavirin.

HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis‐related morbidity

Lyle C. Gurrin, Nadine A. Bertalli, Gregory W. Dalton, Nicholas J. Osborne, Clare C. Constantine, Christine E. McLaren, Dallas R. English, Dorota M. Gertig, Martin B. Delatycki, Amanda J. Nicoll, Melissa C. Southey, John L. Hopper, Graham G. Giles, Gregory J. Anderson, John K. Olynyk, Lawrie W. Powell, Katrina J. Allen, HealthIron Study Investigators – 23 June 2009 – The risk of hemochromatosis‐related morbidity is unknown among HFE compound heterozygotes (C282Y/H63D).

Subscribe to